During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells
Complete report is spread across 51 pages is available @ http://www.reportsnreports.com/reports/282184-remicade-ulcerative-colitis-forecast-and-market-analysis-to-2022.html .
